With the change of life styles brought about by the economic development and the rising incomes, the number of hyperlipidemia patients in China keeps growing, being estimated to reach 160-200 million in the near future.
Atorvastatin, a common drug that can lower blood cholesterol levels, was developed by Pfizer under the trade name of Lipitor. Boasting of nearly 20 years of use in over 100 countries in the real world, atorvastation has proved its efficacy and safety in hundreds of clinical tests and hundreds of millions of clinical medications. Large amounts of evidences and clinical practices have confirmed that atorvastation (10-80 mg) has strong effects in reducing low-density lipoprotein cholesterol (LDL-C). For patients with coronary heart disease, ischemic stroke, diabetes and hypertension, atorvastation is proved to reduce the number of cases of major cardiovascular diseases safely. By the end of 2014, the sales value of atorvastation has surpassed USD 100 billion around the world, creating a fabulous miracle among all the medicines for sale.
After entering China, atorvastatin develops fast with annual sales value rising from less than CNY 70 million in 2005 to CNY 1.374 billion in 2014 and CAGR reaching up to 41% during 2005-2014. Atorvastatin enjoys a vast demand in China. And such companies as Pfizer Inc (Ireland), Pfizer Inc (the US), Topfond and Beijing Jialin Pharmaceutical Co., Ltd occupy the market, among which Pfizer (the US) has the largest market share of about 65% in 2014 with sales value reaching up to CNY 895 million.
As the number of hyperlipidemia patients keeps growing, the sales value of atorvastatin is expected to increase in the next few years.
Readers can get at least the following information from this report:
-sales status of atorvastatin in China
-price of atorvastatin in Chinese market
-major manufacturers of atorvastatin in Chinese market
-share of dosage forms of atorvastatin in China
-market outlook of atorvastatin in China
The author suggests the following groups of people purchase this report:
-manufacturers of cardiovascular drugs
-investors/ research institutions interested in China cardiovascular drug market
-any interest in the Chinese medicine market, please contact CRI for customized survey service